Neutral impactCompany
Dr Reddy's gets DCGI nod for cancer drug's second indication in India
Business Standard 2 hrs ago·21 Oct 2026, 9:27 am
The approval allows toripalimab with cisplatin and paclitaxel as first-line treatment for unresectable advanced, recurrent or metastatic ESCC in adults
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Dr. Reddy's Laboratories (DRREDDY).
- Category: Company.
Why it matters
A routine update for Dr. Reddy's Laboratories. Use the price and stock snapshot to gauge how the market is responding.
